Dechra Pharmaceuticals Beheer

Beheer criteriumcontroles 4/4

De CEO Dechra Pharmaceuticals' is Ian Page, benoemd in Nov2001, heeft een ambtstermijn van 22.17 jaar. De totale jaarlijkse vergoeding van { bedraagt £ 1.04M, bestaande uit 59.9% salaris en 40.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.36% van de aandelen van het bedrijf, ter waarde € 18.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 4.3 jaar.

Belangrijke informatie

Ian Page

Algemeen directeur

UK£1.0m

Totale compensatie

Percentage CEO-salaris	59.9%
Dienstverband CEO	22.2yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ian Page's beloning veranderd ten opzichte van Dechra Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	UK£1m	UK£621k	-UK£28m
Mar 31 2023	n/a	n/a	UK£6m
Dec 31 2022	n/a	n/a	UK£40m
Sep 30 2022	n/a	n/a	UK£49m
Jun 30 2022	UK£2m	UK£597k	UK£58m
Mar 31 2022	n/a	n/a	UK£66m
Dec 31 2021	n/a	n/a	UK£73m
Sep 30 2021	n/a	n/a	UK£64m
Jun 30 2021	UK£3m	UK£551k	UK£56m
Mar 31 2021	n/a	n/a	UK£50m
Dec 31 2020	n/a	n/a	UK£44m
Sep 30 2020	n/a	n/a	UK£39m
Jun 30 2020	UK£2m	UK£517k	UK£34m
Mar 31 2020	n/a	n/a	UK£31m
Dec 31 2019	n/a	n/a	UK£29m
Sep 30 2019	n/a	n/a	UK£30m
Jun 30 2019	UK£3m	UK£500k	UK£31m
Mar 31 2019	n/a	n/a	UK£28m
Dec 31 2018	n/a	n/a	UK£25m
Sep 30 2018	n/a	n/a	UK£30m
Jun 30 2018	UK£3m	UK£500k	UK£36m
Mar 31 2018	n/a	n/a	UK£40m
Dec 31 2017	n/a	n/a	UK£43m
Sep 30 2017	n/a	n/a	UK£35m
Jun 30 2017	UK£3m	UK£490k	UK£26m

Compensatie versus markt: De totale vergoeding ($USD 1.31M ) Ian } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 3.18M ).

Compensatie versus inkomsten: De vergoeding van Ian is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ian Page (62 yo)

22.2yrs

Tenure

UK£1,037,000

Compensatie

Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ian Page	CEO, MD & Executive Director	22.2yrs	UK£1.04m	0.36% € 18.2m
Paul Sandland	CFO & Executive Director	4.8yrs	UK£641.00k	0.010% € 525.6k
Patrick Meeus	Chief Scientific Officer	1.5yrs	geen gegevens	geen gegevens
Jamie Adams	Chief Information Officer	1.6yrs	geen gegevens	geen gegevens
Katy Clough	Chief People Officer	no data	geen gegevens	geen gegevens
Mike Eldred	President of North America	no data	geen gegevens	geen gegevens
Melanie Hall	Company Secretary	6.5yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1PK wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ian Page	CEO, MD & Executive Director	26.6yrs	UK£1.04m	0.36% € 18.2m
Paul Sandland	CFO & Executive Director	4.3yrs	UK£641.00k	0.010% € 525.6k
Geeta Gopalan	Independent Non-Executive Director	less than a year	UK£36.00k	geen gegevens
Lawson MacArtney	Senior Independent Director	7.1yrs	UK£107.00k	0.0052% € 263.8k
Alison Platt	Independent Non-Executive Chairman	3.8yrs	UK£207.00k	0.0033% € 166.7k
Lisa Morrison	Designated Non-Executive Director	4.9yrs	UK£72.00k	0.0012% € 61.9k
John Shipsey	Independent Non-Executive Director	1.6yrs	UK£73.00k	0.00053% € 27.1k

4.3yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1PK wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Dechra Pharmaceuticals Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Less than half of directors are independent

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Investor sentiment improves as stock rises 33%

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Now 20% undervalued after recent price drop

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 22% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Now 21% undervalued after recent price drop

Less than half of directors are independent

Non-Executive Chairman recently bought €119k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Upcoming dividend of UK£0.29 per share

Board Member recently sold €1.0m worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold €1.1m worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: €41.36

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: €38.84

CEO, MD & Executive Director recently sold €12m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Upcoming Dividend of UK£0.24 Per Share

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: €38.52

Non-Executive Director recently bought €28k worth of stock

Non-Executive Director recently bought €28k worth of stock

Independent Non Executive Director recently sold €142k worth of stock

Full year earnings released - EPS €0.33

New 90-day high - €36.48

New 90-day high - €33.70

New 90-day high - €32.96

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur